JP6678656B2 - 新規な可溶性グアニル酸シクラーゼ活性剤およびそれらの使用 - Google Patents

新規な可溶性グアニル酸シクラーゼ活性剤およびそれらの使用 Download PDF

Info

Publication number
JP6678656B2
JP6678656B2 JP2017515074A JP2017515074A JP6678656B2 JP 6678656 B2 JP6678656 B2 JP 6678656B2 JP 2017515074 A JP2017515074 A JP 2017515074A JP 2017515074 A JP2017515074 A JP 2017515074A JP 6678656 B2 JP6678656 B2 JP 6678656B2
Authority
JP
Japan
Prior art keywords
mmol
piperidin
pyridin
piperidine
stirred
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017515074A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017527602A (ja
JP2017527602A5 (enExample
Inventor
アン、マリー、ジャンヌ、ブーイヨ
ネリナ、ドディク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of JP2017527602A publication Critical patent/JP2017527602A/ja
Publication of JP2017527602A5 publication Critical patent/JP2017527602A5/ja
Priority to JP2020035272A priority Critical patent/JP6908747B2/ja
Application granted granted Critical
Publication of JP6678656B2 publication Critical patent/JP6678656B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
JP2017515074A 2014-09-19 2015-09-18 新規な可溶性グアニル酸シクラーゼ活性剤およびそれらの使用 Active JP6678656B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020035272A JP6908747B2 (ja) 2014-09-19 2020-03-02 新規な可溶性グアニル酸シクラーゼ活性剤およびそれらの使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462052537P 2014-09-19 2014-09-19
US62/052,537 2014-09-19
PCT/IB2015/057219 WO2016042536A1 (en) 2014-09-19 2015-09-18 Novel soluble guanylate cyclase activators and their use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020035272A Division JP6908747B2 (ja) 2014-09-19 2020-03-02 新規な可溶性グアニル酸シクラーゼ活性剤およびそれらの使用

Publications (3)

Publication Number Publication Date
JP2017527602A JP2017527602A (ja) 2017-09-21
JP2017527602A5 JP2017527602A5 (enExample) 2018-10-25
JP6678656B2 true JP6678656B2 (ja) 2020-04-08

Family

ID=54238488

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017515074A Active JP6678656B2 (ja) 2014-09-19 2015-09-18 新規な可溶性グアニル酸シクラーゼ活性剤およびそれらの使用
JP2020035272A Active JP6908747B2 (ja) 2014-09-19 2020-03-02 新規な可溶性グアニル酸シクラーゼ活性剤およびそれらの使用
JP2021109106A Pending JP2021155450A (ja) 2014-09-19 2021-06-30 新規な可溶性グアニル酸シクラーゼ活性剤およびそれらの使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020035272A Active JP6908747B2 (ja) 2014-09-19 2020-03-02 新規な可溶性グアニル酸シクラーゼ活性剤およびそれらの使用
JP2021109106A Pending JP2021155450A (ja) 2014-09-19 2021-06-30 新規な可溶性グアニル酸シクラーゼ活性剤およびそれらの使用

Country Status (21)

Country Link
US (2) US9938260B2 (enExample)
EP (1) EP3194384A1 (enExample)
JP (3) JP6678656B2 (enExample)
KR (1) KR20170054508A (enExample)
CN (1) CN106687456B (enExample)
AU (1) AU2015319724B2 (enExample)
BR (1) BR112017005660A2 (enExample)
CA (1) CA2961745A1 (enExample)
CL (1) CL2017000640A1 (enExample)
CO (1) CO2017002506A2 (enExample)
CR (1) CR20170102A (enExample)
DO (1) DOP2017000073A (enExample)
EA (1) EA033697B1 (enExample)
IL (1) IL251094A0 (enExample)
MA (1) MA40583A (enExample)
MX (1) MX2017003621A (enExample)
PE (1) PE20170937A1 (enExample)
PH (1) PH12017500481A1 (enExample)
SG (1) SG11201701915TA (enExample)
WO (1) WO2016042536A1 (enExample)
ZA (1) ZA201701835B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020105189A (ja) * 2014-09-19 2020-07-09 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 新規な可溶性グアニル酸シクラーゼ活性剤およびそれらの使用

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202400446T1 (it) 2014-02-06 2024-11-15 Nxera Pharma Uk Ltd Composti aza biciclici come agonisti del recettore muscarinico
TN2017000092A1 (en) 2014-09-19 2018-07-04 Bayer Pharma AG Benzyl substituted indazoles as bub1 inhibitors.
CN109890379A (zh) 2016-10-11 2019-06-14 拜耳制药股份公司 包含sGC活化剂和盐皮质激素受体拮抗剂的组合产品
WO2019081456A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT
EP3498298A1 (en) 2017-12-15 2019-06-19 Bayer AG The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi)
CA3098475A1 (en) 2018-04-30 2019-11-07 Bayer Aktiengesellschaft The use of sgc activators and sgc stimulators for the treatment of cognitive impairment
EA202092680A1 (ru) 2018-05-15 2021-04-13 Байер Акциенгезельшафт 1,3-тиазол-2-ил-замещенные бензамиды для лечения заболеваний, ассоциированных с сенситизацией нервных волокон
EP3574905A1 (en) 2018-05-30 2019-12-04 Adverio Pharma GmbH Method of identifying a subgroup of patients suffering from dcssc which benefits from a treatment with sgc stimulators and sgc activators in a higher degree than a control group
EP3911675A1 (en) 2019-01-17 2021-11-24 Bayer Aktiengesellschaft Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc)
WO2023237577A1 (en) 2022-06-09 2023-12-14 Bayer Aktiengesellschaft Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602143A (en) 1994-12-08 1997-02-11 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of guanylate cyclase inhibitors
KR20140032505A (ko) 2006-11-09 2014-03-14 알콘 리서치, 리미티드 약물 전달용 수불용성 폴리머 매트릭스
PE20091258A1 (es) * 2007-12-03 2009-09-12 Smithkline Beecham Corp Derivados de piridina como activadores de la guanilato ciclasa soluble
WO2010015653A1 (en) * 2008-08-07 2010-02-11 Smithkline Beecham Corporation Pyrimidine derivatives as activators of soluble guanylate cyclase
WO2010099054A2 (en) * 2009-02-26 2010-09-02 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
DE102009012314A1 (de) * 2009-03-09 2010-09-16 Bayer Schering Pharma Aktiengesellschaft Oxo-heterocyclisch substituierte Alkylcarbonsäuren und ihre Verwendung
JP5636296B2 (ja) 2011-01-20 2014-12-03 公益財団法人微生物化学研究会 塩分含有有機廃液処理剤、並びに、塩分濃度低下剤、塩分含有有機廃液の処理方法、及び包括固定担体
WO2016042536A1 (en) * 2014-09-19 2016-03-24 Glaxosmithkline Intellectual Property Development Limited Novel soluble guanylate cyclase activators and their use

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020105189A (ja) * 2014-09-19 2020-07-09 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 新規な可溶性グアニル酸シクラーゼ活性剤およびそれらの使用
JP2021155450A (ja) * 2014-09-19 2021-10-07 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited 新規な可溶性グアニル酸シクラーゼ活性剤およびそれらの使用

Also Published As

Publication number Publication date
CO2017002506A2 (es) 2017-07-28
DOP2017000073A (es) 2017-04-16
ZA201701835B (en) 2018-12-19
PH12017500481A1 (en) 2017-08-07
EP3194384A1 (en) 2017-07-26
CN106687456B (zh) 2019-12-03
US10472350B2 (en) 2019-11-12
MX2017003621A (es) 2017-07-14
JP2021155450A (ja) 2021-10-07
AU2015319724B2 (en) 2018-05-10
PE20170937A1 (es) 2017-07-13
JP2017527602A (ja) 2017-09-21
WO2016042536A1 (en) 2016-03-24
CA2961745A1 (en) 2016-03-24
MA40583A (fr) 2016-03-24
JP6908747B2 (ja) 2021-07-28
EA201790655A1 (ru) 2017-08-31
US9938260B2 (en) 2018-04-10
KR20170054508A (ko) 2017-05-17
CR20170102A (es) 2017-07-17
US20170305888A1 (en) 2017-10-26
EA033697B1 (ru) 2019-11-18
CL2017000640A1 (es) 2017-10-06
US20180194756A1 (en) 2018-07-12
IL251094A0 (en) 2017-04-30
AU2015319724A1 (en) 2017-04-06
CN106687456A (zh) 2017-05-17
JP2020105189A (ja) 2020-07-09
BR112017005660A2 (pt) 2017-12-19
SG11201701915TA (en) 2017-04-27

Similar Documents

Publication Publication Date Title
JP6678656B2 (ja) 新規な可溶性グアニル酸シクラーゼ活性剤およびそれらの使用
JP5658664B2 (ja) １，２−二置換複素環式化合物
EP2531501B1 (en) Apoptosis signal-regulating kinase 1 inhibitors
JP2016530292A (ja) 新規な可溶性グアニル酸シクラーゼ活性剤およびそれらの使用
CN112105385A (zh) Irak降解剂和其用途
HK1249509A1 (zh) 作为irak-4抑制剂的吲唑及氮杂吲唑化合物
TW202500565A (zh) Shp2磷酸酶抑制劑及其使用方法
BR112015009168B1 (pt) Composto de fórmula estrutural xi ou um sal do mesmo, uso de um composto e composição farmacêutica
JP6673853B2 (ja) ヘテロシクリル−ブタンアミド誘導体
TW201506018A (zh) 二雜芳基化合物及其用途
CN105143185A (zh) 新的嘧啶和吡啶化合物以及它们的用途
KR20160037985A (ko) 옥소퀴나졸리닐-부탄아미드 유도체
AU2013354552A1 (en) Substituted pyridopyrazines as Syk inhibitors
EP3480193A1 (en) Novel pyrazole derivative as alk5 inhibitor and uses thereof
CN109867660A (zh) 含季铵离子的四氢异喹啉酰胺化合物及其药物用途
KR20160023854A (ko) 프탈라진 유도체
TW202136237A (zh) RORγt抑制劑及其製備方法和用途
CN116655625A (zh) 作为sos1抑制剂的化合物及其应用
KR20070022753A (ko) 인다졸 및 인돌론 유도체 및 이의 약제로서의 용도
CN105980373A (zh) 新的可溶性鸟苷酸环化酶活化剂及它们的用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180824

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180824

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180911

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190507

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190425

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191106

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200218

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200317

R150 Certificate of patent or registration of utility model

Ref document number: 6678656

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350